Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
Insmed (INSM) reported a Q2 2026 adjusted loss of 52 cents per share, narrower than the Zacks Consensus loss of 69 cents. Revenue rose 296% to $425.5 million, beating $389.7 million. Brinsupri uptake drove a 34% stock jump and raised 2026 Brinsupri guidance to $1.25-$1.40 billion.
How this was made
The 30-second read
Why it matters
The earnings print plus a material Brinsupri guidance and peak-sales increase changes the forward revenue trajectory and valuation expectations, while pipeline updates (FDA filing for newly diagnosed MAC and TPIP study enrollment) add longer-dated optionality.
Market read
This is a company-specific earnings and guidance catalyst with explicit numbers (revenue, patient starts, and 2026 guidance), explaining the large same-day stock move.
What to watch
The article notes a large non-cash contingent consideration gain excluded from adjusted results; traders should watch whether cash generation and operating expense growth keep pace with revenue ramp.
Background
Insmed has two marketed drugs, Arikayce and Brinsupri, with Brinsupri approved in August 2025 and now in its third full quarter of revenue contribution.
Ticker impact
Insmed reported Q2 results and raised 2026 Brinsupri revenue guidance to $1.25-$1.40B after strong organic patient uptake, driving a 34% stock jump.
Bullish bias for follow-through, with elevated volatility as the market reprices 2026 Brinsupri growth and peak sales assumptions.
The article cites specific Q2 revenue beats, ~7,000 organic patient starts, and an explicit guidance and peak-sales increase, which directly changes forward revenue expectations.
Market effects
Reinforces positive read-through for commercial-stage rare pulmonary drug launches, especially where payer access and organic starts are highlighted.
No specific regional demand shock beyond noting Arikayce growth in ex-U.S. markets.
Limited; the key driver is company-specific Brinsupri uptake and FDA/Japan label expansion plans.
Counterpoint
The guidance raise may already be heavily priced after a 34% move, so incremental upside could be harder unless patient starts and payer approvals continue to exceed expectations.
Key entities
- companyInsmed
Reported Q2 2026 results, highlighted organic Brinsupri patient uptake, and raised 2026 Brinsupri revenue guidance and peak sales outlook.
- drugBrinsupri
Commercial-stage therapy whose organic patient starts and payer access metrics drove the guidance increase.
- drugArikayce
Another marketed product with Q2 revenue growth and maintained 2026 guidance.
- regulatorFDA
Received an FDA filing to expand Arikayce use to newly diagnosed MAC patients.
